CONNECT WITH US
HealthTech

HealthTech

Zimmer submits Monogram robot to FDA

MedTech Dive logo

Published on

Add as a preferred source on Google
Zimmer submits Monogram robot to FDA

The company is targeting Food and Drug Administration clearance next year for an autonomous orthopedic robot.

Zimmer has filed a 510(k) submission for an autonomous version of its Monogram orthopedic robot. Permission granted by Monogram Orthopedics

Zimmer Biomet has filed for 510(k) clearance for an autonomous version of its Monogram orthopedic robot, a company spokesperson told MedTech Dive in an email.

CEO Ivan Tornos said at an investor event this week that Zimmer made the filling on Monday and hopes to receive Food and Drug Administration clearance sometime next year.

Tornos said he expects Monogram to be a “game-changing platform,” citing the robot’s safety, efficiency, ease of use and accuracy.

Zimmer acquired Monogram Technologies in 2025 for $177 million. At the time, the company had a semi-autonomous robot used in total knee replacement surgeries, and was working to develop a fully autonomous version that would be hands-free and activated using foot pedals.

Monogram’s robot differs from Zimmer’s existing orthopedic robot, Rosa, in that it can be used with CT imaging.

In a clinical trial of Monogram, Tornos said no safety events were reported. The robot helped with faster bone preparation and landmarking ahead of procedures.

At a Stifel conference on Sunday, two orthopedic surgeons discussed the new robot. They said it has potential for meaningful time savings, reduced instrument tray use and better accuracy, Stifel analyst Rick Wise wrote in a research note. The automated bone cutting capabilities could help reduce procedure-related physical strains for surgeons, they added.

“I wouldn't be surprised if there's some back and forth with the FDA, given that this is new-to-the-world technology,” Tornos said.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.